Skip to content

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Protocol and rationale for a randomised, double-blind, placebo-controlled phase 3 trial of admilparant (BMS-986278), an oral lysophosphatidic acid receptor 1 antagonist, in patients with idiopathic pulmonary fibrosis: ALOFT-IPF

Abstract Introduction Idiopathic pulmonary fibrosis (IPF) is associated with progressive loss of lung function and poor prognosis. There remains a need for novel therapies for patients with IPF. Admilparant, an oral lysophosphatidic acid receptor 1 antagonist, slowed lung function decline and was well tolerated in a ph...

Toby M. Maher, Fernando J. Martinez, M. Kreuter et al. · 0 citations
Open access Sep 2026

High intensity interval training in interstitial lung disease: a randomized controlled trial.

RATIONALE Pulmonary rehabilitation (PR) is an effective guideline-recommended intervention for people with interstitial lung disease (ILD). However, not all participants experience clinically meaningful improvements. The current PR approach may not represent the optimal form of exercise training for people with ILD....

L. Dowman, Anthony K. May, Catherine J. Hill et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.